
BRIM — Investor Relations & Filings
BRIM Biotechnology, Inc. specializes in the application of translational science to develop innovative therapies for unmet medical needs. The company utilizes its proprietary Pigment Epithelium-Derived Factor (PEDF) Derived Short Peptide (PDSP) technology platform, which leverages neurotrophic properties to stimulate cell proliferation, wound healing, and tissue regeneration. Its research pipeline primarily targets ophthalmology and degenerative conditions, featuring lead candidates such as BRM421 for dry eye syndrome, BRM424 for neurotrophic keratitis, and BRM521 for osteoarthritis. Operating through an integrated model, the company advances drug candidates to the proof-of-concept stage before pursuing strategic licensing and partnerships for late-stage development. BRIM also incorporates precision medicine and bioinformatics to explore combination therapies and enhance therapeutic outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45772690 | 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | ||
| 45772689 | 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | ||
| 45772688 | 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | ||
| 45772687 | 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | ||
| 45772686 | 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | ||
| 45772685 | 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese | ||
| 45746302 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45746232 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741513 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741321 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 45544696 | 115年第1季財務報告書 — 202601_6885_AI1.pdf | 2026-05-11 | Chinese | ||
| 33964967 | 115年4月變更登記 | 2026-04-10 | Chinese | ||
| 33964970 | 公司基本資料 | 2026-04-10 | Chinese | ||
| 33902475 | 公告本公司限制員工權利新股收回註銷完成變更登記 | 2026-04-09 | Chinese | ||
| 33893046 | 115年04月僑外投資持股 | 2026-04-09 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Vcanbio Cell & Gene Engineering Corp., Ltd
Focuses on stem cell bio-banking, genetic testing, and cell…
|
600645 | CN | Professional, scientific and te… |
|
VECTUS BIOSYSTEMS LIMITED
Develops therapeutics to reverse fibrosis and hypertension …
|
VBS | AU | Professional, scientific and te… |
|
Veradermics, Inc
Clinical-stage biopharmaceutical company developing medical…
|
MANE | US | Professional, scientific and te… |
|
Vera Therapeutics, Inc.
Clinical-stage biotech developing treatments for immunologi…
|
VERA | US | Professional, scientific and te… |
|
Veritas In Silico Inc.
A drug discovery company developing mRNA-targeting therapeu…
|
130A | JP | Professional, scientific and te… |
|
ViGenCell Inc.
Develops immune cell therapies to treat cancer and other in…
|
308080 | KR | Professional, scientific and te… |
|
Viking Therapeutics, Inc.
Clinical-stage biopharma developing therapies for metabolic…
|
VKTX | US | Professional, scientific and te… |
|
Vimta Labs Ltd.
Contract research and testing organization for life science…
|
VIMTALABS | IN | Professional, scientific and te… |
|
Vinext S.p.A.
Develops sustainable technology for the oenology and agri-f…
|
VNXT | IT | Professional, scientific and te… |
|
Virax Biolabs Group Ltd
Biotechnology company specializing in immune response detec…
|
VRAX | US | Professional, scientific and te… |
BRIM via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52650/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52650 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52650 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52650 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52650}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BRIM (id: 52650)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.